Business Description
Viracta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92765F1084
Description
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.25 | |||||
| Equity-to-Asset | -0.3 | |||||
| Debt-to-Equity | -2.56 | |||||
| Debt-to-EBITDA | -0.43 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -33.7 | |||||
| 3-Year EPS without NRI Growth Rate | -36.9 | |||||
| 3-Year FCF Growth Rate | -33.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 35.47 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 77.93 | |||||
| 9-Day RSI | 71.69 | |||||
| 14-Day RSI | 64.39 | |||||
| 6-1 Month Momentum % | -74.59 | |||||
| 12-1 Month Momentum % | -64.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.76 | |||||
| Quick Ratio | 0.76 | |||||
| Cash Ratio | 0.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | 53.69 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -390.27 | |||||
| ROA % | -99.4 | |||||
| ROIC % | -214.18 | |||||
| ROC (Joel Greenblatt) % | -11740.63 | |||||
| ROCE % | -361.57 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.13 | |||||
| EV-to-EBITDA | -0.13 | |||||
| EV-to-Forward-Revenue | 0.72 | |||||
| EV-to-FCF | -0.14 | |||||
| Earnings Yield (Greenblatt) % | -769.23 | |||||
| FCF Yield % | -350.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Viracta Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.008 | ||
| Beta | -0.18 | ||
| Volatility % | 107.53 | ||
| 14-Day RSI | 64.39 | ||
| 14-Day ATR (€) | 0.011281 | ||
| 20-Day SMA (€) | 0.15915 | ||
| 12-1 Month Momentum % | -64.57 | ||
| 52-Week Range (€) | 0.131 - 1.11 | ||
| Shares Outstanding (Mil) | 39.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Viracta Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Viracta Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Viracta Therapeutics Inc Frequently Asked Questions
What is Viracta Therapeutics Inc(STU:RYIS)'s stock price today?
The current price of STU:RYIS is €0.19. The 52 week high of STU:RYIS is €1.11 and 52 week low is €0.13.
When is next earnings date of Viracta Therapeutics Inc(STU:RYIS)?
The next earnings date of Viracta Therapeutics Inc(STU:RYIS) is 2025-03-07 Est..
Does Viracta Therapeutics Inc(STU:RYIS) pay dividends? If so, how much?
Viracta Therapeutics Inc(STU:RYIS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers